Cytokinetics Management

Management criteria checks 2/4

Cytokinetics' CEO is Robert Blum, appointed in Feb 2006, has a tenure of 18.25 years. total yearly compensation is $8.75M, comprised of 9% salary and 91% bonuses, including company stock and options. directly owns 0.32% of the company’s shares, worth €19.41M. The average tenure of the management team and the board of directors is 3.2 years and 13.5 years respectively.

Key information

Robert Blum

Chief executive officer

US$8.8m

Total compensation

CEO salary percentage	9.0%
CEO tenure	18.3yrs
CEO ownership	0.3%
Management average tenure	3.2yrs
Board average tenure	13.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Robert Blum's remuneration changed compared to Cytokinetics's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$9m	US$790k	-US$526m
Sep 30 2023	n/a	n/a	-US$527m
Jun 30 2023	n/a	n/a	-US$540m
Mar 31 2023	n/a	n/a	-US$431m
Dec 31 2022	US$9m	US$742k	-US$389m
Sep 30 2022	n/a	n/a	-US$282m
Jun 30 2022	n/a	n/a	-US$216m
Mar 31 2022	n/a	n/a	-US$258m
Dec 31 2021	US$6m	US$709k	-US$215m
Sep 30 2021	n/a	n/a	-US$229m
Jun 30 2021	n/a	n/a	-US$156m
Mar 31 2021	n/a	n/a	-US$135m
Dec 31 2020	US$5m	US$682k	-US$127m
Sep 30 2020	n/a	n/a	-US$114m
Jun 30 2020	n/a	n/a	-US$140m
Mar 31 2020	n/a	n/a	-US$132m
Dec 31 2019	US$3m	US$656k	-US$122m
Sep 30 2019	n/a	n/a	-US$118m
Jun 30 2019	n/a	n/a	-US$110m
Mar 31 2019	n/a	n/a	-US$105m
Dec 31 2018	US$3m	US$630k	-US$106m
Sep 30 2018	n/a	n/a	-US$120m
Jun 30 2018	n/a	n/a	-US$131m
Mar 31 2018	n/a	n/a	-US$132m
Dec 31 2017	US$3m	US$612k	-US$128m

Compensation vs Market: Robert's total compensation ($USD8.75M) is above average for companies of similar size in the German market ($USD3.34M).

Compensation vs Earnings: Robert's compensation has increased whilst the company is unprofitable.

CEO

Robert Blum (59 yo)

18.3yrs

Tenure

US$8,751,057

Compensation

Mr. Robert I. Blum has been Chief Executive Officer, President and Director of Cytokinetics, Incorporated since January 22, 2007 and serves as its Principal Financial Officer. Mr. Blum previously served as...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Robert Blum	CEO, President	18.3yrs	US$8.75m	0.32% $ 19.4m
Robert Wong	VP & Chief Accounting Officer	5yrs	US$1.04m	0.020% $ 1.2m
Fady Malik	Executive Vice President of Research & Development	11.9yrs	US$4.44m	0.083% $ 5.0m
Andrew Callos	Executive VP & Chief Commercial Officer	3.2yrs	US$3.20m	0.024% $ 1.4m
James Spudich	Co-Founder & Member of Scientific Advisory Board	26.8yrs	US$21.94k	no data
Jeff Lotz	Vice President of Sales & Operations	2.7yrs	no data	no data
Matt Yang	Vice President of Corporate Finance and Financial Planning & Analysis	less than a year	no data	no data
Steven Cook	Senior Vice President of Global Supply Chain Operations & Technical Operations	no data	no data	no data
Kari Loeser	VP & Chief Compliance Officer	2.5yrs	no data	no data
John Faurescu	VP, Associate General Counsel & Corporate Secretary	no data	no data	no data
Scott Jordan	Senior Vice President of Global Marketing & Commercial Strategy	3yrs	no data	no data
YulyMae DiNapoli	Vice President of Human Resources	no data	no data	no data

3.2yrs

Average Tenure

59yo

Average Age

Experienced Management: KK3A's management team is considered experienced (3.2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Robert Blum	CEO, President	17.3yrs	US$8.75m	0.32% $ 19.4m
James Spudich	Co-Founder & Member of Scientific Advisory Board	no data	US$21.94k	no data
B. Parshall	Independent Director	11.3yrs	US$529.02k	0.0095% $ 574.5k
Santo Costa	Independent Director	13.5yrs	US$524.02k	0.0095% $ 574.5k
James H. Sabry	Co-Founder & Chairman of Scientific Advisory Board	16.1yrs	US$41.50k	no data
Nancy Wysenski	Independent Director	3.5yrs	US$519.02k	0.012% $ 694.3k
John Henderson	Independent Chairman	15.3yrs	US$559.02k	0.026% $ 1.6m
John Lowe	Member of Scientific Advisory Board	no data	no data	no data
Thomas Pollard	Member of Scientific Advisory Board	no data	no data	no data
David Morgans	Member of Scientific Advisory Board	7.8yrs	US$942.23k	no data
Lawrence S. Goldstein	Member of Scientific Advisory Board	no data	no data	no data
John Solaro	Member of Scientific Advisory Board	no data	no data	no data

13.5yrs

Average Tenure

69.5yo

Average Age

Experienced Board: KK3A's board of directors are seasoned and experienced ( 13.5 years average tenure).

Cytokinetics Management

Management criteria checks 2/4

Key information

Recent management updates

Cytokinetics, Incorporated Appoints Sung H. Lee as Executive Vice President, Effective as of May 8, 2024

Cytokinetics, Incorporated, Annual General Meeting, May 15, 2024

Cytokinetics, Incorporated Announces Resignation of Ching W. Jaw as Chief Financial Officer, Effective February 23, 2024

Cytokinetics, Incorporated Announces Resignation of Ching W. Jaw, Senior Vice President, Effective February 23, 2024

Insufficient new directors

VP & Chief Accounting Officer recently sold €83k worth of stock

Recent updates

Cytokinetics, Incorporated Appoints Sung H. Lee as Executive Vice President, Effective as of May 8, 2024

Cytokinetics, Incorporated to Report Q1, 2024 Results on May 08, 2024

Cytokinetics, Incorporated, Annual General Meeting, May 15, 2024

Cytokinetics Presents Additional 48-Week Data from Forest-Hcm, the Open Label Extension Clinical Study of Aficamten, At the American College of Cardiology 73rd Annual Scientific Session

Cytokinetics, Incorporated Provides Revenue Guidance for 2024

Full year 2023 earnings released: US$5.45 loss per share (vs US$4.33 loss in FY 2022)

New major risk - Revenue and earnings growth

Cytokinetics, Incorporated to Report Q4, 2023 Results on Feb 27, 2024

Cytokinetics, Incorporated Announces Resignation of Ching W. Jaw as Chief Financial Officer, Effective February 23, 2024

Cytokinetics, Incorporated Announces Resignation of Ching W. Jaw, Senior Vice President, Effective February 23, 2024

Novartis Pursuit of Cytokinetics Reportedly Cools

Novartis Reportedly in Advanced Talks to Buy Cytokinetics

Cytokinetics, Incorporated Announces Positive Results from Sequoia-Hcm, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy

Now 20% undervalued

Cytokinetics Presents Results from COURAGE-ALS At the 34th International Symposium on ALS/MND

Insufficient new directors

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: US$1.35 loss per share (vs US$1.52 loss in 3Q 2022)

Cytokinetics, Incorporated to Report Q3, 2023 Results on Nov 02, 2023

Cytokinetics, Incorporated Provides Update on Cardiac Myosin Inhibitor Programs and Plans to Build a Specialty Cardiology Franchise at Virtual Investor & Analyst Day

New minor risk - Share price stability

Cytokinetics, Incorporated Presents Baseline Characteristics from SEQUOIA-HCM at the HCM Society

Second quarter 2023 earnings released: US$1.34 loss per share (vs US$0.23 loss in 2Q 2022)

Cytokinetics, Incorporated to Report Q2, 2023 Results on Aug 03, 2023

Cytokinetics, Incorporated Presents New Data in Patients with Non-Obstructive Hcm from Cohort 4 of Redwood-Hcm in Late-Breaking Clinical Trial Session At the European Society of Cardiology Heart Failure 2023 Congress

Cytokinetics, Incorporated Announces Initiation of Phase 1 Clinical Study of CK-4021586

First quarter 2023 earnings released: US$1.38 loss per share (vs US$1.05 loss in 1Q 2022)

Now 22% undervalued after recent price drop

Now 20% undervalued after recent price drop

Full year 2022 earnings released: US$4.33 loss per share (vs US$2.80 loss in FY 2021)

Cytokinetics, Incorporated to Report Q4, 2022 Results on Mar 01, 2023

Cytokinetics, Incorporated Announces Outcome of FDA Advisory Committee Vote On Omecamtiv Mecarbil

Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-3828136

VP & Chief Accounting Officer recently sold €83k worth of stock

Cytokinetics, Incorporated Presents New Data at the American Heart Association Scientific Sessions 2022

Third quarter 2022 earnings released: US$1.52 loss per share (vs US$0.95 loss in 3Q 2021)

Cytokinetics, Incorporated to Report Q3, 2022 Results on Nov 03, 2022

Cytokinetics, Incorporated Announces Continuation of COURAGE-ALS Following First Interim Analysis

Cytokinetics, Incorporated Presents New Data From REDWOOD-HCM OLE in Late Breaking Clinical Trial Session at the HCM Society Scientific Sessions

Second quarter 2022 earnings released: US$0.23 loss per share (vs US$0.86 loss in 2Q 2021)

Cytokinetics and The ALS Association Announce Release of Updated PRO-ACT Database Including Data From Cytokinetics' Completed ALS Clinical Trials

Cytokinetics, Incorporated to Report Q2, 2022 Results on Aug 04, 2022

Cytokinetics, Incorporated Provides Update on New Drug Application

Cytokinetics Announces Start of Open-Label Extension Study for Patients Completing COURAGE-ALS

Cytokinetics, Incorporated Announces Additional Data from Redwood-HCM Presented At the American Society of Echocardiography 33Rd Annual Scientific Sessions

First quarter 2022 earnings released: US$1.05 loss per share (vs US$0.66 loss in 1Q 2021)

Cytokinetics, Incorporated to Report Q1, 2022 Results on May 04, 2022

Cytokinetics, Incorporated Announces Retirement of Mark A. Schlossberg as Senior Vice President, Legal, General Counsel and Secretary, Effective May 13, 2022

Cytokinetics, Incorporated Announces Changes to Board of Directors

Cytokinetics Announces Results From METEORIC-HF and Additional Data From GALACTIC-HF Presented at the American College of Cardiology 71st Annual Scientific Session

Cytokinetics, Incorporated Announces Cohort 4 of REDWOOD-HCM is Open to Enrollment

Cytokinetics, Incorporated Announces Cohort 4 of REDWOOD-HCM is Open to Enrollment

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Cytokinetics, Incorporated Provides Earnings Guidance for the Year 2022

Cytokinetics, Incorporated Announces Start of SEQUOIA-HCM, a Phase 3 Clinical Trial of Aficamten in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Cytokinetics, Incorporated Announces Resignation of Robert M. Califf as Member of the Board of Directors

Cytokinetics, Incorporated Announces Topline Results From METEORIC-HF

Cytokinetics, Incorporated to Report Q4, 2021 Results on Feb 24, 2022

Cytokinetics, Incorporated Announces FDA Acceptance of New Drug Application for Omecamtiv Mecarbil for the Treatment of Heart Failure with Reduced Ejection Fraction

Cytokinetics, Incorporated Announces Positive Topline Results from Cohort 3 of REDWOOD-HCM

Cytokinetics, Incorporated announced that it expects to receive $19.999996 million in funding from RTW Investments, LP

Cytokinetics, Incorporated Announces New Data Presented At the 32nd International Symposium on ALS/MND

Cytokinetics, Incorporated Announces Receipt of Breakthrough Therapy Designation from FDA for Aficamten

Third quarter 2021 earnings released: US$0.95 loss per share (vs US$0.046 loss in 3Q 2020)

Cytokinetics Announces Results From REDWOOD-HCM and GALACTIC-HF to Be Presented in Late Breaking Clinical Trials Session at the HFSA Annual Scientific Meeting

Second quarter 2021 earnings released: US$0.86 loss per share (vs US$0.68 loss in 2Q 2020)

Cytokinetics, Incorporated Updates Its Financial Guidance for 2021

Cytokinetics, Incorporated Announces COURAGE-ALS Is Open to Enrollment

Cytokinetics, Incorporated has completed a Follow-on Equity Offering in the amount of $275 million.